

The *Advanced Practitioner Society for Hematology and Oncology* (APSHO) is pleased to present the APSHO Patient/Advocacy Perspectives Poster track during JADPRO Live, an annual conference for advanced practitioners (APs) in oncology and hematology. Introduced at the 2022 conference, patient/advocacy posters provided valuable insight into patient issues and available resources as well as connection opportunities between patient advocacy organizations and APs.

The mission of APSHO is to improve the quality of care for patients on the cancer journey by supporting critical issues in educational, clinical, and professional development for APs. APSHO comprises more than 4,000+ APs in oncology and hematology, including nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, and pharmacists. We believe an interdisciplinary team approach to cancer treatment offers the best support for the outcomes, quality of life and survivorship of our patients. APs understand that the importance of the patient perspective cannot be overstated, and they are uniquely positioned to incorporate feedback and insight from patients and their advocates into clinical practice. Through the APSHO Patient/Advocacy Perspectives Poster track, we can identify best practices for key components of care including communication, education, symptom management, and caregiver support. Gaining a better understanding of the patient's perspective provides ideas and insights for improving the overall quality of cancer care.

Invitation to submit an abstract

APSHO invites patient advocacy organizations and patients to partner in submitting abstracts for poster presentation during JADPRO Live 2023, to be held November 9-12 at the Orlando World Center Marriott in Orlando, Florida.

Submission deadline

Abstract submitters must complete all requirements by **11:59 pm EDT on September 22, 2023**, for the abstract to be considered for presentation in the APSHO Patient/Advocacy Perspectives Poster track.

Abstract Submission Guidelines

Who may submit

- Patient advocacy groups involved in cancer care
- Patients on the cancer care continuum, partnering with a patient advocacy group
- Caregivers of patients with cancer, partnering with a patient advocacy group

Note: A caregiver is defined as a spouse, family member/loved one, friend, neighbor, or other non-healthcare provider assisting the patient during the cancer journey.

Examples of topics for submission

- An intervention, guideline, practice, or procedure that made a positive impact on care or quality of life

- An example of a collaboration between patient and health care team resulting in improved care
- Care interventions that resulted in improved symptom or side effect management
- Processes that resulted in improved communication, access to care, clinic experience, engagement, self-care, or support
- Impact of advocacy initiatives, assistance programs, complementary therapies, patient/caregiver support, survivorship care, research
- Educational materials, processes, classes, groups or other methods providing support for patient and caregivers

Note: Abstracts may not mention specific medications, therapies, devices for treatment or biopharmaceutical companies.

Submission process

All abstract details will be submitted via an electronic submission system. Submitters may save their work and come back to complete it. **Submissions must be completed by the deadline of September 22nd for an abstract to be reviewed.**

Submitting author requirements

- If patient: full name, email, phone number and address; must have at least one advocacy organization representative co-author
- If advocacy organization representative: full name, credentials if applicable, title/position, organization name, email, phone number, and address
- Abstract title (75 characters or less)
- Complete body of abstract including appropriate subheadings (500 words or less)
- Entry of co-authors, if applicable
- Declaration of the role of the authors in the work/content presented in the abstract
- Confirmation of original authorship (completed by submitting author)
- Disclosure form (each author on the abstract is required to complete one electronically)
- Consent for abstract review and sharing of identifiable information (if patient submitting)
- Completed Copyright Transfer Agreement for Abstracts (lead or representative author approved by the lead author must complete)
- Permissions, as applicable (may be uploaded as supporting documentation)
 - Patient advocacy groups submitting abstracts containing identifiable patient information must upload a statement of permission from the patient.
- References, if applicable (encouraged but not required; may be uploaded as supporting documentation)
- Statement of need for financial assistance (e.g., travel support, poster production or medical writing) if the abstract is accepted (statement of need is optional, but must be provided at the time of submission)

Co-author information required

- If patient: full name, email, phone, address

- If advocacy organization representative: full name, credentials if applicable, title/position, organization name, email, phone, address
- Self-completed disclosure form (each author listed on the abstract must complete one)

Note: It is preferred that the lead author submits the abstract and presents the poster if the abstract is accepted. If a co-author on the abstract will be attending the conference and presenting the poster, that co-author should be the author who submits the abstract. If extenuating circumstances occur before the conference, and it is necessary for an author different than the submitter to present, the author must have been a co-author on the original submission, and the abstract submission coordinator should be notified as soon as possible. Authors may not be added and changes to the submission are not permitted after the submission deadline.

Abstract title

The title at the time of submission will be the final title used in all references to the abstract and poster. Acronyms and abbreviations are not permitted in the title. The title is not included in the word count.

Abstract body and word count

Abstracts should be no more than 500 words, including section headings. Acronyms may be used within the abstract after the words are spelled out at first use, with the acronym following in parentheses.

Section headings

The abstract should tell a brief story and provide a meaningful snapshot of what will be presented in more detail within a poster, and must be organized with short, one-word section (paragraph) headings. Section headings are included in the word count. Examples of common section headings:

- Background (Context, Setting)
- Intervention (Process, Actions)
- Findings (Discovery, Conclusions)
- Implications (Discussion, Recommendations)

Tables

Tables are not allowed in the body of the abstract but may be used in poster development.

References and Permissions

References and/or permissions may not be included in the body of the abstract and therefore are not included in the word count. Permissions are required. References are optional. Both must be uploaded as a PDF.

Note: Abstract content should not have been previously presented or published and should not be submitted elsewhere, under consideration for presentation or publication.

Statement of need

Limited financial support is available from APSHO to submitters of accepted abstracts. Submitting authors must upload a statement of need during submission, describing the type of support requested (e.g., financial, or other assistance) for poster presentation of an accepted abstract.

Correspondence

The submitting author may be contacted to clarify co-author information, role, or contributions. All correspondence regarding submitted abstracts will be directed to the submitting author, with a copy to the patient advocacy organization partner if applicable. Likewise, submitters may contact the abstract coordinator for questions at any time during the process.

Review process

Abstract reviews

Abstracts will be reviewed by a steering committee of advanced practitioners. Review of the abstract will be focused on the following questions:

- If the abstract is submitted by a patient or caregiver, is there an advocacy organization partner as co-author?
- Is the content/context focused on the patient perspective?
- Is the topic relevant to and significant for the care of a patient on the cancer care continuum?
- Does the abstract provide necessary permissions?

Notifications

Submitting authors whose abstracts are accepted for poster presentation will be contacted by the abstract coordinator via email by or before October 6, 2023.

Poster Presentations

When an abstract is accepted, the poster presenters will be provided important information regarding next steps in the process, such as: poster numbers or other identifiers, specifications for poster development, poster presenter tasks, presentation dates and times, and additional requirements as needed.

Poster presenter responsibilities

- Completing poster presenter tasks in the electronic submission system prior to the conference (see below)
- Development and printing of the poster
- Transport or shipping of the poster to the conference venue
- Displaying the poster in the exhibit hall Thursday, November 9th
- Attending two moderated poster sessions to discuss the poster, answer questions, and interact with conference attendees, Friday, November 10th and Saturday November 11th (times to be announced)
- Bringing materials on the organization and/or available programs for the take-one table

Poster presenter tasks

Tasks with deadlines will be completed in the electronic system, such as:

- Confirming profile information
- Uploading a presenter photo
- Uploading a presenter bio

- Uploading the final poster as a one-page PDF
- Providing the presenter's JADPRO Live registration confirmation number
- Recording a short audio or video statement about the poster

Poster Exposure and Benefits

Posters, abstracts, and presenting author information will be available to registered conference attendees during the live conference. Each organization is asked to bring materials on their services/programs available for patients for the “take-one” table in the exhibit hall. One (1) all-access conference registration will be provided to the presenting poster representative for access into the exhibit hall and to attend sessions. For 3+ submissions, please contact Jessica Tamasi (jessica.tamasi@broadcastmed.com) for information on additional registrations. Posters will also be available via an e/poster gallery. In addition, posters will remain available during the JADPRO Live on-demand period November 20 through December 31, 2023. In January 2024 an email blast will be deployed to the JADPRO advanced practice list of 8000+ with a link to all posters.

For more information regarding patient posters, please contact Jessica Tamasi, Jessica.tamasi@broadcastmed.com.

APSHO would like to acknowledge and thank founding supporter for the APSHO Patient/Advocacy Perspective Poster Program, Pfizer Oncology, and additional supporters, Bristol Myers Squibb and Genmab US, Inc.